A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy Catheters
← catalyst calendarNCT05386342 · readout ≤ 315 d
Sponsored by LeMaitre Vascular (industry) · LMAT — their whole pipeline →. With Avania.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
112estimated
Sites
3
Countries
Germany, Switzerland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-11 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Thrombus
- Embolus
- Occlusion; Vessel
Intervention
- Device: TufTex Over-the-Wire Embolectomy Catheter
Primary outcomes
what the primary-completion date above is the date OFPerformance objective is the technical success being <30% residual stenosis
measured 1 month post index procedure
Safety objective is defined as acceptable safety outcomes during the procedure and at follow-up
measured 1 month post index procedure
Permalink · LMAT's whole pipeline · Catalyst calendar · Every registered study · What changed